Redeye initiates coverage of Lipigon, a biotech company developing Lipisense, a new first-in-class ANGPTL-4-targeting candidate, based on modern, state-of-the-art, antisense technology. We believe Lipisense could reduce blood fat in the several million people suffering from SHTG, a condition of extreme triglyceride blood levels that leaves patients at high risk for pancreatitis—implying potential blockbuster status for the candidate.